440 related articles for article (PubMed ID: 1531076)
21. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
Rivier C; Rivier J; Mormede P; Vale W
Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
[TBL] [Abstract][Full Text] [Related]
22. Vasopressin-induced antipyresis in the medial amygdaloid nucleus of conscious rats.
Federico P; Veale WL; Pittman QJ
Am J Physiol; 1992 May; 262(5 Pt 2):R901-8. PubMed ID: 1534208
[TBL] [Abstract][Full Text] [Related]
23. Comparison of selective arginine vasopressin V1 and V2 receptor antagonists on burn shock in the rat.
Sun K; Lin BC; Wang CH; Zhu HN
Cardiovasc Res; 1991 Apr; 25(4):265-9. PubMed ID: 1884385
[TBL] [Abstract][Full Text] [Related]
24. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
[TBL] [Abstract][Full Text] [Related]
26. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 8-D-arginine vasopressin analogues, modified in position 1 as antagonists of the vasopressor response to the parent hormone.
Lammek B; Derdowska I; Melin P
Pol J Pharmacol Pharm; 1988; 40(4):423-8. PubMed ID: 3222181
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological evaluation of d(CH2)5Tyr(Me)AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery.
Clineschmidt BV; Lis EV
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):72-84. PubMed ID: 2950833
[TBL] [Abstract][Full Text] [Related]
29. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and some pharmacologic properties of five novel V1 or V1/V2 antagonists of AVP.
Lammek B; Wang YX; Derdowska I; Franco R; Gavras H
Peptides; 1989; 10(5):1109-12. PubMed ID: 2608555
[TBL] [Abstract][Full Text] [Related]
31. Desensitization of renal vasopressin-stimulated adenylate cyclase by a vasopressor and antidiuretic antagonist, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-ethyl)-D-tyrosine, 4-valine]arginine vasopressin.
Chang P; Kimura K
Biochem Biophys Res Commun; 1987 Apr; 144(2):770-8. PubMed ID: 3579941
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
[TBL] [Abstract][Full Text] [Related]
33. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
Pang CC; Leighton KM
Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of arginine vasopressin receptors in the rat testis.
Meidan R; Hsueh AJ
Endocrinology; 1985 Jan; 116(1):416-23. PubMed ID: 2981073
[TBL] [Abstract][Full Text] [Related]
35. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
Croiset G; De Wied D
Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
[TBL] [Abstract][Full Text] [Related]
36. V1 vs. combined V1+V2 vasopressin blockade after hemorrhage in conscious dogs.
Liard JF
Am J Physiol; 1988 Dec; 255(6 Pt 2):H1325-9. PubMed ID: 2974249
[TBL] [Abstract][Full Text] [Related]
37. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
Varga C; Somlai C; Baláspiri L; László FA
Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
[TBL] [Abstract][Full Text] [Related]
38. Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors.
Musabayane CT; Forsling ML; Balment RJ
Ren Fail; 1997 Jan; 19(1):23-32. PubMed ID: 9044449
[TBL] [Abstract][Full Text] [Related]
39. New antagonists of the vasopressin receptor mediated contraction in rat tail artery.
Petrusewicz J; Damasiewicz B; Kaliszan R; Juzwa W; Lammek B; Derdowska I
Pharmacol Res; 1992; 25(2):167-72. PubMed ID: 1386154
[TBL] [Abstract][Full Text] [Related]
40. A V1-vascular vasopressin antagonist suitable for radioiodination and photoaffinity labeling.
Thibonnier M; Chehade N; Hinko A
Am J Hypertens; 1990 Jun; 3(6 Pt 1):471-5. PubMed ID: 2369497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
